Ionis is a leader in RNA-based therapies. Its spinal muscular atrophy drug Spinraza, marketed by partner Biogen, is the first RNA-based therapy to achieve blockbuster status. The firm’s antisense oligonucleotide, or ASO, technology faces strong compe… [305 chars]
Narrow-Moat Ionis Expands Its Cardiology and Neurology Portfolio; Positive Long-Term Outlook
RELATED ARTICLES
